University of Colorado, Denver
New data suggests that the current treatment for pediatric adamantinomatous craniopharyngioma (CPA) may not be as effective as it could be.
Current treatment regimens for pediatric CPA are limited to surgery and radiation therapy. This pilot study seeks to identify biologically rational therapeutics for the medical treatment of adamantinomatous CPA by confirming the overexpression of specific molecules.
Inclusion Criteria: 1. Patients between 0-21 years of age. 2. Patients with the diagnosis or clinical suspicion of craniopharyngioma in whom planned clinical management will include tissue sampling. Exclusion Criteria: 1. Patients in whom final pathology does not demonstrate adamantinomatous craniopharyngioma 2. Patients in whom tissue specimen is not obtained/available 3. Patients over 21 years of age. 4. Patients who choose not to participate
If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.